Login / Signup

Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma.

Jens TijtgatXenia GeeraertsAnais BoissonLatoya StevensManon VounckxIris DirvenJulia Katharina SchwarzeSteven RaeymaeckersRamses ForsythIvan Van RietSandra TuyaertsKaren Willard-GalloBart Neyns
Published in: Journal for immunotherapy of cancer (2024)
ClinicalTrials.gov identifier NCT03707808.
Keyphrases
  • dendritic cells
  • bone marrow
  • immune response
  • regulatory t cells
  • early stage
  • nk cells
  • high dose
  • acute myeloid leukemia
  • cell therapy
  • low dose